BDKRB1 and myeloid sarcoma: In marked contrast, the activation of B1R, assessed via treatment with the B1 agonist DABK, inhibited the progression of EAE and neuroinflammation by modulating the permeability of the BBB, a pivotal step that triggers CNS inflammation, an event which is directly related to the development of MS [30], [41].